SIGFOX
6.1.2022 11:02:07 CET | Business Wire | Press release
Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, today announces its partnership with HT Micron, a Brazilian expert in advanced semiconductor solutions, and Nowi, a semiconductor company that specializes in the development of energy harvesting power management technology, to explore and unlock the benefits of integrating energy harvesting into Sigfox devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005406/en/
This collaboration marks the first step for Sigfox towards a commercial development of energy harvesting modules to equip IoT devices and contribute to more sustainability in IoT. Key use cases are applications in Smart metering, industrial sensoring, asset tracking and air quality monitoring.
During the research phase, HT Micron has worked on creating the innovative semiconductor solution to be integrated with Nowi’s Energy Harvesting PMIC (Power Management Integrated Circuit) designed especially for low power IoT devices. Equipped on Sigfox devices and powered by the 0G technology, this solution will help reduce battery consumption and offer longer autonomy while reducing the total cost of ownership.
Nowi PMIC is designed to efficiently extract power from ambient energy sources like light and vibration to charge a variety of energy storage elements such as a rechargeable battery or a capacitor. It is best suited for most low power applications like distributed IoT sensors and TV remote controls for example.
“The low power consumption of Sigfox solutions is particularly well suited to being powered by ambient energy harvesting. As many Sigfox-based applications require intermittent communication intervals, this allows for trickle charging a storage element with energy harvesting in between transmissions ,” explains Chris Juliano, CCO at Nowi .
Sigfox and HT Micron have been working together for several years already and HT Micron was identified as a strategic partner for this project as they have the expertise to create innovative modules and they consider energy harvesting essential for IoT mass adoption with sustainability.
“We are glad to take this next step with Sigfox and explore energy harvesting solutions as a new way to create added value to our end customers and help them improve their environmental impact ,” says Edelweis Ritt, CIO at HT Micron .
“This collaboration with Nowi and HT Micron is another proof point towards our ambition to create IoT solutions that will help our clients preserve the environment by greatly reducing their energy consumption. We are looking forward to the development of this new kind of devices and to the positive impact they will generate ” says Benjamin Jooris, Client & Ecosystem Success Director at Sigfox.
The first step of this project is a development kit integrating Nowi’s PMIC solution with HT Micron’s Sigfox system-in-package, to be used for testing purposes by R&D and product development teams. First information will be presented at CES 2022 (5-7 January in Las Vegas) at Nowi’s booth (#51733) to gather customer and developers’ feedback. Customers can register to receive the development kit. Next, Sigfox, Nowi and HT Micron will create a mass production module that can be used by any type of device maker.
This announcement comes as part of strengthening Sigfox's strategy to help reduce the human impact on the environment with IoT, and it will be soon followed by other solutions based on energy harvesting as new projects are already in discussion.
****
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Nowi
Nowi is a semiconductor company founded in 2016, based in Delft, the Netherlands, with regional offices in the US and in Shanghai.
Nowi has developed energy harvesting power management ICs that combine top harvesting performance with the world’s smallest assembly footprint and lowest BOM cost. Thereby it simplifies the design process and lowers the threshold for any company to develop ‘Plug & Forget’ products.
About HT Micron
HT Micron provides advanced semiconductor solutions. The portfolio includes memories for computers, cell phones and smart TVs, as well as System-in-Package connectivity solutions for the Internet of Things. HT Micron is a Brazilian company, having as the main shareholder the South Korean group HANA Micron, and is based in the city of São Leopoldo, RS, in South Brazil.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
